BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/14/2023 6:13:55 AM | Browse: 156 | Download: 625
 |
Received |
|
2023-03-28 12:32 |
 |
Peer-Review Started |
|
2023-03-28 12:32 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2023-07-04 06:54 |
 |
Revised |
|
2023-07-11 14:47 |
 |
Second Decision |
|
2023-07-31 03:05 |
 |
Accepted by Journal Editor-in-Chief |
|
2023-08-04 05:20 |
 |
Accepted by Executive Editor-in-Chief |
|
2023-09-06 08:02 |
 |
Articles in Press |
|
2023-09-06 08:02 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2023-09-28 03:09 |
 |
Publish the Manuscript Online |
|
2023-11-14 06:13 |
ISSN |
1948-9358 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Basic Study |
Article Title |
Vascular endothelial growth factor B improves impaired glucose tolerance through insulin-mediated inhibition of glucagon secretion
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Yu-Qi Li, Lu-Yang Zhang, Yu-Chi Zhao, Fang Xu, Zhi-Yong Hu, Qi-Hao Wu, Wen-Hao Li and Ya-Nuo Li |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
The National Natural Science Foundation of China |
31771284 |
The Basic Research Project of Yantai Science and Technology Innovation and Development Plan |
2022JCYJ026 |
The Natural Science Foundation of Shandong province |
ZR202111250163 |
Yantai Science and Technology Plan Project |
2022YD062 |
|
Corresponding Author |
Ya-Nuo Li, PhD, Professor, Department of Pathophysiology, School of Basic Medicine, Binzhou Medical University, No. 346 Guanhai Road, Laishan District, Yantai 264000, Shandong Province, China. liyanuo@bzmc.edu.cn |
Key Words |
Vascular endothelial growth factor B; Insulin-mediated; Glucagon secretion; Prediabetes; Impaired glucose tolerance |
Core Tip |
Impaired glucose tolerance (IGT) is an abnormal metabolic stage between the normal state and diabetes, which belongs to prediabetes. Therefore, intervention in IGT can effectively reduce the incidence rate of diabetes. The pathological mechanism of IGT is related to glucose homeostasis imbalance and decreased insulin sensitivity. Currently, vascular endothelial growth factor B (VEGFB) has been reported to have the effect of restoring glucose tolerance and improving insulin sensitivity. Therefore, the use of VEGFB as a target for intervention has become the focus of current research. This research mainly illustrates the role of VEGFB in promoting insulin and glucagon secretion to alleviate IGT and its potential molecular mechanism. |
Publish Date |
2023-11-14 06:13 |
Citation |
Li YQ, Zhang LY, Zhao YC, Xu F, Hu ZY, Wu QH, Li WH, Li YN. Vascular endothelial growth factor B improves impaired glucose tolerance through insulin-mediated inhibition of glucagon secretion. World J Diabetes 2023; 14(11): 1643-1658 |
URL |
https://www.wjgnet.com/1948-9358/full/v14/i11/1643.htm |
DOI |
https://dx.doi.org/10.4239/wjd.v14.i11.1643 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345